Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, and a quick way to test potential treatments.

Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, and a quick way to test potential treatments.

Merck, a leading science and technology company, today announced a five-year agreement with Genetix Biotherapeutics to provide analytical and biosafety release testing services for its portfolio of ...

The FDA’s standard 60-day review window for ImmunityBio’s resubmitted application seeking expanded approval for Anktiva expires Thursday. ・Wall Street expects a 15% sequential jump in Q1 revenue, ...

Today in Boston Celtics history, Bill Sharman was traded to the Celtics in 1951 from the then Fort Wayne Pistons.

It's the tragedy that shocked Hollywood and the world: Oscar-winning actor Gene Hackman, 95, and his wife, Betsy Arakawa, 64, ...

A Hiroshima-University-led research team has discovered a key gene responsible for the initiation of gemma development, ...

"The gene-therapy approach in this study is a new avenue that can complement and potentially augment what will surely be a multidisciplinary solution to one day regenerate human limbs." He said the ...

A 10-market geographic build-up covering the U.S., Canada, France, Germany, Spain, Italy, the UK, Australia, Japan and South ...

The global hearing loss gene therapy market size is calculated at USD 1.33 billion in 2026 and is expected to reach around ...

As more products reach the market, therapy developers partner with researchers and regulators to deliver N-of-1 treatments to patients.

A novel strategy that combines computational and experimental approaches has allowed researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas ...